The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers

Clinical Pharmacology and Therapeutics

Volumn 95, Issue 2, 2014, Pages 208-215

  Smink, P A ^a   Miao, Y ^a   Eijkemans, M J C ^b   Bakker, S J L ^a   Raz, I ^c   Parving, H H ^d,e   Hoekman, J ^a   Grobbee, D E ^b   De Zeeuw, D ^a   Heerspink, H J Lambers ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY DISEASES; LOSARTAN; RISK REDUCTION BEHAVIOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84893805586     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.191     Document Type: Article

References (28)

1. Chobanian, A.V. et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42, 1206-1252 (2003).
2. Dahlöf, B. et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359, 995-1003 (2002).
3. Lewis, E.J. et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001).
4. Lambers Heerspink, H.J. & de Zeeuw, D. Dual RAS therapy not on target, but fully alive. Nephron. Clin. Pract. 116, c137-c142 (2010).
5. Hou, F.F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889-1898 (2007).
6. Miao, Y. et al. Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 44-50 (2011).
7. Brenner, B.M. et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001).
8. Roscioni, S. et al. Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia 54, 2965-2967 (2011).
9. Eijkelkamp, W.B. et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J. Am. Soc. Nephrol. 18, 1540-1546 (2007).
10. Ravid, M., Brosh, D., Ravid-Safran, D., Levy, Z. & Rachmani, R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch. Intern. Med. 158, 998-1004 (1998).
11. Hsu, C.Y., Iribarren, C., McCulloch, C.E., Darbinian, J. & Go, A.S. Risk factors for end-stage renal disease: 25-year follow-up. Arch. Intern. Med. 169, 342-350 (2009).
12. Keane, W.F. et al.; RENAAL Study Investigators. The risk of developing endstage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int. 63, 1499-1507 (2003).
13. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008).
14. Mann, J.F. et al.; ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008).
15. Jamerson, K. et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359, 2417-2428 (2008).
16. Mann, J.F. et al.; ASCEND Study Group. Avosentan for overt diabetic nephropathy. J. Am. Soc. Nephrol. 21, 527-535 (2010).
17. Nissen, S.E. & Wolski, K. Rosiglitazone revisited: An updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch. Intern. Med. 170, 1191-1201 (2010).
18. Barter, P.J. et al.; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357, 2109-2122 (2007).
19. James, W.P. et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N. Engl. J. Med. 363, 905-917 (2010).
20. Blind, E., Dunder, K., de Graeff, P.A. & Abadie, E. Rosiglitazone: A European regulatory perspective. Diabetologia 54, 213-218 (2011).
21. Stevens, R.J., Kothari, V., Adler, A.I. & Stratton, I.M.; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin. Sci. 101, 671-679 (2001).
22. Kengne, A.P. et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur. J. Cardiovasc. Prev. Rehabil. 18, 393-398 (2011).
23. Parving, H.H., Persson, F., Lewis, J.B., Lewis, E.J. & Hollenberg, N.K.; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 358, 2433-2446 (2008).
24. Smink, P.A. et al. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers. Eur. J. Prev. Cardiol. (2013); e-pub ahead of print 6 March 2013.
25. Parving, H.H. et al.; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N. Engl. J. Med. 367, 2204-2213 (2012).
26. Moons, K.G. et al. Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart 98, 683-690 (2012).
27. Brenner, B.M. et al.; RENAAL Study Investigators. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J. Renin. Angiotensin. Aldosterone. Syst. 1, 328-335 (2000).
28. Rodby, R.A. et al. The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol. Dial. Transplant. 15, 487-497 (2000).